The phase III CONVINCE trial aimed to assess the efficacy and safety of first-line icotinib versus chemotherapy in lung adenocarcinoma patients with exon 19/21 EGFR mutations [37]. This evidence concerns the gene EGFR and lung adenocarcinoma.